Aster DM Healthcare Q4FY26: Revenue Up 18%, EBITDA Up 26%
Aster DM Healthcare's combined proforma entity (Aster+QCIL) reported Q4FY26 revenue of ₹2,361 crore, up 18% YoY. Operating EBITDA grew 25% to ₹517 crore. Standalone revenue was ₹1,182 crore (up 18% YoY), with EBITDA at ₹244 crore (up 26% YoY). The merger is expected to complete in Q1 FY27.
The announcement covers quarterly financial results, significant operational improvements, and a major corporate action (merger), all of which have a substantial impact on the company's valuation and future prospects.
The company reported strong year-on-year growth in revenue and EBITDA for both the combined entity and standalone operations. The merger is progressing well with significant shareholder approval, and the outlook appears positive.
Aster DM Healthcare Limited has released its investor presentation for the quarter and year ended March 31, 2026. The combined proforma entity (Aster + QCIL) reported an 18% year-on-year growth in revenue for Q4FY26, reaching ₹2,361 crore. Total patient volumes increased by 12% to 1.93 million, with occupancy rising to 61%. Operating EBITDA for the combined entity saw a robust 25% YoY growth, reaching ₹517 crore, with EBITDA margins at 21.9% compared to 20.7% in Q4FY25. Return on Capital Employed (RoCE) improved by approximately 290 basis points to 21.1% in Q4FY26. The merger proposal received strong shareholder approval, with 96.68% voting in favor, and is expected to be completed in Q1 FY27. In standalone results, Aster DM Healthcare reported an 18% YoY revenue growth to ₹1,182 crore for Q4FY26, with Operating EBITDA rising by 26% to ₹244 crore and margins improving to 20.7% from 19.3% in the previous year. Normalised PAT (Post-NCI) grew by 32% to ₹140 crore.
What to do with a filing like this
Aster DM Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Healthcare Limited. Read the original for the full detail.